Virginia Hernández-Gea
Metge Hepatòleg, HCBPublicacions destacades
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Autors:Referència: Journal Of Hepatology 2019. -
Porto-sinusoidal vascular disease: proposal and description of a novel entity
Autors:Referència: Lancet Gastroenterology & Hepatology 2019. -
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis
Autors:Referència: Liver International 2019. -
TIPS Indications and Contraindications—Pushing the Limits: Is Earlier Better?
Autors:Referència: Current Hepatology Reports 2019. -
Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis.
Autors:Referència: Liver International 2019. -
Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer
Autors:Referència: Clinical And Translational Gastroenterology 2019. -
Idiopathic Portal Hypertension
Autors:Referència: Hepathology 2018. -
Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury.
Autors:Referència: Journal Of Hepatology 2018. -
Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis
Autors:Referència: 2018. -
Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.
Autors:Referència: 2018.
Projectes destacats
-
La autofagia endotelial gobierna la respuesta de la célula hepática estrellada al daño hepático: regeneración o fibrosis? Análisis del secretoma endotelial para el desarrollo de nuevos tratamientos antibibroticos
Investigador/a principal: Virginia Hernandez GeaFinançador: Instituto de Salud Carlos IIICodi: PI17/00398Durada: 01/01/2018 - 31/12/2020 -
Papel de la autofagia en la modulación de la disfunción endotelial y la fibrosis: caracterización de una nueva diana terapéutica para el desarrollo de nuevos tratamientos antifibróticos
Investigador/a principal: Virginia Hernández GeaFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Instituto de Salud Carlos IIICodi: FIS PI14/00182Durada: 01/01/2014 - 31/12/2017 -
HEPTROMIC: Genomic predictors and oncogenic drivers in hepatocellular carcinoma
Investigador/a principal: Jessica Zucman RossiFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); European Commission (FP7-2010-Health.2.4.1-6 )Durada: 03/09/2012 - 31/05/2013 -
Autophagy During hepatic stellate cell activation in alcoholic liver injury
Investigador/a principal: Scott L. FriedmanFinançador: Mount Sinai School of Medicine (Sede o evento); NIAAA/RFA-AA-11-002Durada: 01/01/2011 - 30/09/2012 -
Role of Stellate Cells in Hepatic Fibrosis
Investigador/a principal: Scott L. FriedmanFinançador: Mount Sinai School of Medicine (Sede o evento); NIH, NIDDKDurada: 01/01/2011 - 30/09/2012